| Similar Articles |
|---|
 |
Pharmaceutical Executive
February 1, 2006
Joanna Breitstein |
Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem.   |
Chemistry World
January 3, 2013
Andrew Turley |
TB drug milestone for bedaquiline Bedaquiline (sirturo) has become the first drug to be approved in the US for the treatment of multi-drug resistant tuberculosis |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease |
BusinessWeek
April 1, 2010
Bennett & Randall |
Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists. |
Pharmaceutical Executive
September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? |
AboutSafety
September 11, 2001 |
Tuberculosis (TB) TB is a potentially severe contagious disease that is spread from person to person via the air. The TB germs may spray into the air if a person with TB disease of the lungs or throat coughs, speaks or sneezes... |
Fast Company
March 2015
J.J. McCorvey |
How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone. |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
Pharmaceutical Executive
December 1, 2005
Alana Klein |
Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
Pharmaceutical Executive
October 1, 2005
Jill Wechsler |
Washington Report: Antivirals: Meeting a World of Need The international fight against AIDS requires drugs -- and policy. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
American Family Physician
December 1, 2005 |
Tuberculosis: What You Should Know A patient hand-out on the disease, who is susceptible, its treatment and medication recommendation. |
Chemistry World
May 29, 2015
Phillip Broadwith |
Achillion partners with Janssen to boost hepatitis C pipeline Janssen will invest $225 million in Achillion shares, and has promised performance milestone payments worth up to $1.1 billion, plus royalties on any sales. |
Pharmaceutical Executive
September 1, 2006
Kieran Hartsough |
Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
July 16, 2011
Melly Alazraki |
HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales. |
American Family Physician
July 15, 2004
Joel E. Gallant |
HIV Counseling, Testing, and Referral By the year 2005, the CDC seeks to achieve the following: reduce annual new HIV infections from the current estimated 40,000 cases to 20,000 cases through the use of interventions such as counseling, HIV testing, and referral |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool
October 17, 2008
Brian Orelli |
Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results. |
Scientific American
February 2009
John Rennie |
Tuberculosis, The Unromantic Killer Tuberculosis has never stopped being one of the world's most lethal infections |
Salon.com
May 18, 2000
Sabin Russell |
The dream and the coming disaster AIDS threatens to ravage the hopes of South Africa's young democracy. Don't expect leaders to get excited because a few companies cut the cost of HIV drugs. |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
Pharmaceutical Executive
September 1, 2010 |
Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
BusinessWeek
September 2, 2010
Simeon Bennett |
David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS. |
The Motley Fool
December 21, 2004
Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
AskMen.com
Dave Golokhov |
Truvada With more and more studies finding successful AIDS prevention, it looks like we're getting closer to finding a cure. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
February 18, 2010
Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool
March 31, 2011
Brian Orelli |
Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious. |
American Family Physician
January 15, 2006
Ann M. Khalsa |
Preventive Counseling, Screening, and Therapy for the Patient with Newly Diagnosed HIV Infection The epidemic of HIV continues, and the infection is converting into a treatable chronic disease; therefore, it is increasingly important for family physicians to be current with and comfortable in providing basic care to patients infected with HIV. |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. |
HHMI Bulletin
Aug 2010 |
Bishai Named Director of K-RITH A prominent tuberculosis researcher and doctor will become the first permanent director of the KwaZulu-Natal Research Institute for Tuberculosis and HIV. |
Chemistry World
September 16, 2008
Hepeng Jia |
Research Initiative Targets China's Major Killer Diseases A new epidemics research initiative is targeting China's biggest killer diseases: HIV/AIDS, tuberculosis (TB) and virulent hepatitis. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
Scientific American
October 2008
John Rennie |
Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed. |
BusinessWeek
April 1, 2010 |
The Case for PrEP The acronym stands for pre-exposure prophylaxis, meaning the use of therapeutic drugs to prevent infection. In the absence of an HIV vaccine, here are three reasons PrEP may be the next best thing. |
Salon.com
May 8, 2001
Daryl Lindsey |
The "Joe Camel" ads of AIDS? The FDA says ads for drugs to suppress HIV are making false promises, and could be contributing to an epidemic of unsafe sex... |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
BusinessWeek
March 26, 2009
Aili McConnon |
Gilead Sciences: High-Performing Pharmaceutical Gilead owes much of its success to making it easier for patients to comply with complex and uncomfortable drug regimens. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back. |
Salon.com
July 17, 2000
Nina Teicholz |
When drugs take a holiday Could taking a break from protease inhibitors be the secret to treating AIDS? A new case of a 40-year-old man in Philadelphia shows it's possible. |
American Family Physician
May 15, 2002
Alex H. Krist & Amy Crawford-Faucher |
Management of Newborns Exposed to Maternal HIV Infection The management of infants whose mothers are infected with the human immunodeficiency virus involves minimizing the risk of vertical transmission of HIV, recognizing neonatal HIV infection early, preventing opportunistic infections, and addressing psychosocial issues... |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
American Journal of Nursing
March 2010
Bradley-Springer et al. |
Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV. |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
The Motley Fool
January 27, 2011
Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
